Health Care

Labcorp Holdings, Inc. (NYSE: LH) or Labcorp benefits from the solid execution of its strategic priorities. Investment in targeted high-growth areas should drive the momentum. The company faces headwinds from macroeconomic uncertainties and growing foreign exchange issues. The stock carries a Zacks...

The Medical Instruments industry has been witnessing a gradual transition from remote healthcare and contactless services during the pandemic to its original space of point-of-care testing, heavy as well as minimally invasive implants, elective procedures, and so on. This industry is highly...

Bristol Myers Squibb (NYSE: BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) on Dec 29, 2024. The subcutaneous formulation of Opdivo is co-formulated with Halozyme's proprietary recombinant human...

Roche (OTC: RHHBY) obtained a Breakthrough Therapy Designation for its investigational oral therapy inavolisib for treating adult breast cancer patients in the United States. The FDA granted this designation to inavolisib in combination with Ibrance (palbociclib) and Faslodex (fulvestrant) to treat...

Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor, Keytruda plus vibostolimab, its investigational anti-TIGIT antibody, as adjuvant treatment for patients with resected high-risk melanoma. Data from a...

Needham downgraded Masimo Corporation (NASDAQ: MASI), noting that though Apple Inc (NASDAQ: AAPL) royalties are not certain, but are mostly priced into MASI shares. Wednesday, a U.S. appeals court temporarily halted the government commission's import ban on certain...

Luna Innovations Inc (NASDAQ: LUNA) disclosed a strategic investment of $50 million from White Hat Capital Partners. The company will partially use the proceeds to fund the acquisition of Silixa, which was announced today, for $21.5 million in upfront cash consideration and up to an...

The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.  Tarpeyo was first approved in...

Robotic surgeries are going mainstream for a good reason: they make it easier for doctors to perform complex surgeries. Monogram Orthopedics Inc. (NASDAQ: MGRM), which aims to revolutionize orthopedic joint replacement surgery with its robotic technology, just got one step closer to achieving that...

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Agilent Technologies, Inc. (NYSE: A) to report quarterly earnings at $1.35 per share on revenue of $1.67 billion after the closing bell. Agilent...

Moleculin Biotech Inc (NASDAQ: MBRX) provided a preliminary update on recent clinical activity from annamycin lead development programs. Annamycin is the company's next-generation anthracycline that has been designed to be non-cardiotoxic (unlike currently prescribed anthracyclines)...

Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX) released Phase 2 study results from two signal-seeking pipeline programs in focal onset seizures and anhedonia. The investigational selective NaV 1.6 inhibitor, NBI-921352, licensed from Xenon Pharmaceuticals Inc (...

Needham analyst Mike Matson reiterated a Buy rating on Masimo Corporation (NASDAQ: MASI) with a price target of $136. On Thursday, the ITC upheld a January judge's decision in an exclusion order, which found Apple Inc. (NASDAQ: AAPL) guilty of infringing...